The Eisai company has got approval by the Ministry of Health of the Russian Federation on the use of antiepileptic drug Fycompa® in children

1. State Register of Medicinal Products. The registration certificate of a medicinal product Fykompa® (LP-002200; August 23, 2013) (in Russian). Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=af1b55d0-26eb-4fe3-b594-db3792f89e2f&t (accessed December 23, 2020).

2. Fogarasi A., Flamini R., Milh M., et al. Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic-clonic seizures. Epilepsia. 2020; 61 (1): 125–37. https://doi.org/10.1111/epi.16413.

3. Renfroe J.B., Mintz M., Davis R., et al. Adjunctive perampanel oral suspension in pediatric patients from ≥2 to <12 years of age with epilepsy: pharmacokinetics, safety, tolerability, and efficacy. J Child Neurol. 2019; 34 (5): 284–94. https://doi.org/10.1177/0883073819827407.

4. International Bureau for Epilepsy. Japanese Declaration on Epilepsy: 2013. Available at: https://www.ibe-epilepsy.org/japanese-declarationon-epilepsy-2013/ (accessed December 23, 2020).

5. Epilepsy Data and Statistics. Epilepsy Prevalence in the United States. Available at: https://www.cdc.gov/epilepsy/data/index.html#:~:text=Epilepsy%20Prevalence%20in%20the%20United%20States&text=This%20is%20about%203.4%20million,in%20the%20data%20table%20below (accessed December 23, 2020).

6. National Institute of Neurological Disorders and Stroke. The epilepsies and seizures: hope through research. What are the epilepsies? Available at: https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Hope-Through-Research/Epilepsies-and-Seizures-Hope-Through#230253109 (accessed December 23, 2020).